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We have previously demonstrated that the biosynthe-
sis of the C7-cyclitol, called valienol (or valienamine), of
the -glucosidase inhibitor acarbose starts from the cy-
clization of sedo-heptulose 7-phosphate to 2-epi-5-epi-
valiolone (Stratmann, A., Mahmud, T., Lee, S., Distler, J.,
Floss, H. G., and Piepersberg, W. (1999) J. Biol. Chem.
274, 10889–10896). Synthesis of the intermediate 2-epi-5-
epi-valiolone is catalyzed by the cyclase AcbC encoded
in the biosynthetic (acb) gene cluster of Actinoplanes sp.
SE50/110. The acbC gene lies in a possible transcription
unit, acbKLMNOC, cluster encompassing putative bio-
synthetic genes for cyclitol conversion. All genes were
heterologously expressed in strains of Streptomyces livi-
dans 66 strains 1326, TK23, and TK64. The AcbK protein
was identified as the acarbose 7-kinase, which had been
described earlier (Drepper, A., and Pape, H. (1996) J.
Antibiot. (Tokyo) 49, 664–668). The multistep conversion
of 2-epi-5-epi-valiolone to the final cyclitol moiety was
studied by testing enzymatic mechanisms such as dehy-
dration, reduction, epimerization, and phosphorylation.
Thus, a phosphotransferase activity was identified mod-
ifying 2-epi-5-epi-valiolone by ATP-dependent phospho-
rylation. This activity could be attributed to the AcbM
protein by verifying this activity in S. lividans strain
TK64/pCW4123M, expressing His-tagged AcbM. The His-
tagged AcbM protein was purified and subsequently
characterized as a 2-epi-5-epi-valiolone 7-kinase, pre-
sumably catalyzing the first enzyme reaction in the bio-
synthetic route, leading to an activated form of the in-
termediate 1-epi-valienol. The AcbK protein could not
catalyze the same reaction nor convert any of the other
C7-cyclitol monomers tested. The 2-epi-5-epi-valiolone
7-phosphate was further converted by the AcbO protein
to another isomeric and phosphorylated intermediate,
which was likely to be the 2-epimer 5-epi-valiolone
7-phosphate. The products of both enzyme reactions
were characterized by mass spectrometric methods. The
product of the AcbM-catalyzed reaction, 2-epi-5-epi-vali-
olone 7-phosphate, was purified on a preparative scale
and identified by NMR spectroscopy. A biosynthetic
pathway for the pseudodisaccharidic acarviosyl moiety
of acarbose is proposed on the basis of these data.
The -glucosidase inhibitor acarbose (part of the amylostatin
complex) (Fig. 1), produced by strains of the genera Actino-
planes and Streptomyces, is a member of an unusual group of
bacterial (mainly actinomycete) secondary metabolites, all of
which inhibit various -glucosidases, especially in the intestine
(1, 2). Acarbose is produced industrially using developed
strains of Actinoplanes sp. SE50/110. It is predominantly used
in the treatment of diabetes patients, enabling them to better
utilize starch- or sucrose-containing diets by slowing down the
intestinal release of -D-glucose. The pseudotetrasaccharide
acarbose consists of an unsaturated cyclitol (valienol), a 4-ami-
no-4,6-dideoxyglucose, and maltose. The valienol and 4-amino-
4,6-dideoxyglucose are linked via an amino bridge mimicking
an N-glycosidic bond. This acarviosyl moiety is primarily re-
sponsible for the inhibitory effect on -glucosidases. Biosyn-
thetically, these compounds resemble aminoglycoside antibiot-
ics (3, 4). Dependent on the carbon sources in the fermentation
medium, Actinoplanes sp. SE50/110 produces also higher ho-
mologs of acarbose, which differ in the numbers of glucose
residues that are linked to the reducing and nonreducing end of
the acarviosyl moiety (Fig. 1). The C7-aminocyclitol units are
considered to be similar to other common structural motifs
observed in bacterial secondary metabolites (4). The transition
from primary to secondary metabolism in the cyclitol pathway
in Actinoplanes sp. SE50/110 is catalyzed by the AcbC protein.
The acbC gene was expressed heterologously in Streptomyces
lividans employing the same reaction conditions as used in in
vitro studies on dehydroshikimate synthase (dehydroquinate
synthase, AroB) proteins. Its product was shown to be a C7-
cyclitol synthase using sedo-heptulose 7-phosphate as sub-
strate for the production of 2-epi-5-epi-valiolone (5). Until now,
no other intermediate for the biosynthesis of acarbose has been
identified.
The trehalase inhibitor validamycin A (cf. Fig. 1B) is an
antifungal antibiotic used as a crop protectant. Validamycins
are produced by Streptomyces hygroscopicus ssp. limoneus and
consist of two similar C7-cyclitol units, one belonging to the
valienol family (valienamine) and the other to a saturated
6-hydroxy derivative thereof (called validamine). In the biosyn-
thetic pathway for validamycin, 2-epi-5-epi-valiolone has also
been identified as the first precursor for these two cyclitol
units. In this pathway, the feeding of various other potential
precursors had led to the identification of some intermediates,
including 5-epi-valiolone, valienone, and valienamine (cf. Fig.
1) (6, 7). In contrast, similar feeding experiments revealed
2-epi-5-epi-valiolone to be the only precursor that was incorpo-
rated into acarbose (8). Therefore, fundamental differences in
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the two pathways leading to the very similar end products are
likely to exist.
In this study, we show that, during the biosynthesis of acar-
bose in Actinoplanes sp. SE50/110, the cyclitol precursor 2-epi-
5-epi-valiolone is phosphorylated, forming the intermediate
2-epi-5-epi-valiolone 7-phosphate, by the enzyme AcbM as a
first step in its conversion to the valienol moiety. Beyond this,
we found that AcbO catalyzed the next conversion step, leading
to an isomeric phosphorylated substance with the same molec-
ular mass, most likely the epimerization product of 2-epi-5-epi-
valiolone 7-phosphate to 5-epi-valiolone 7-phosphate. These
findings, together with the genetic record from the acb gene
cluster, provided evidence for the postulate of a new biosyn-
thetic pathway for the acarviosyl moiety of acarbose, resem-
bling those for activation (by phosphorylation and subsequent
nucleotidylation) and modification of hexoses to be incorpo-
rated into oligo- or polysaccharides by glycosyl transfer (3, 4, 9).
The fact of 7-O-phosphorylation in addition points to the need
of an inactivating protection group already in the cyclitol in-
termediates and the oligosaccharidic end product(s) inside the
producing cell. This requirement is underlined by the existence
of a second 7-phosphotransferase gene, acbK, which is localized
in the same transcription unit together with the acbM and
other putative cyclitol biosynthetic genes and encodes a cyto-
plasmic acarbose 7-kinase. AcbK introduces a phosphate group
into the same position of the cyclitol moiety of the oligosaccha-
FIG. 1. Chemical structures of two
-glucosidase inhibitors containing
C7-cyclitols. A, acarbose; B, validamycin
A; C, C7-cyclitols. Valienamine is not
shown as an extra structure because it is
represented by the cyclitol moiety of acar-
bose including the NH2 group at C-1.
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ridic end product, but does not use monomeric cyclitol precur-
sors such as 2-epi-5-epi-valiolone as substrates.
MATERIALS AND METHODS
Bacterial Strains, Plasmids, and Growth Conditions
The bacterial strains and plasmids used in this study are listed in
Table I. The following strains of S. lividans 66 were used as the hosts in
expression experiments for the heterologous production of Acb proteins:
strain TK64 for AcbL, AcbM, and AcbO; strain TK23 for AcbK and
AcbN; and strain 1326 for AcbC. The recombinant strains were rou-
tinely cultured at 28 °C on soya fluor-mannitol-agar (SMA) agar plates
(10), yeast extract-malt extract medium (YEME) medium with 10.3 or
34% sucrose (11), or protoplast regeneration medium (SPMR) plates
(12); Actinoplanes sp. SE50/110 was cultured in MD50 medium (2). To
maintain plasmids pIJ4123 and pIJ6021 and their recombinant deriv-
atives, media were supplemented with kanamycin (50 mg/liter). The
thiostrepton-inducible expression of the cloned acbC, acbL, acbM, and
acbO genes in S. lividans TK64 was carried out according to Takano et
al. (13), with the exception that thiostrepton was used at a concentra-
tion of 10 g/ml, and the incubation time after induction was prolonged
to 24 h. Recombinant Escherichia coli strains were grown at 37 °C in
LB broth or on LB agar plates (14) supplemented with ampicillin
(100 mg/liter).
Cloning, Manipulation, and Sequencing of DNA
The techniques for all manipulations and the transformation of re-
combinant DNA molecules and their analysis by restriction and se-
quencing were performed according to standard protocols or as de-
scribed earlier (5, 11, 15). The general strategy for cloning the
acbKLMNO genes into the expression vectors indicated in Table I with
an N-terminal His-tagged fusion peptide was as follows. The genes were
first amplified by PCR from the genomic DNA of Actinoplanes sp.
SE50/110 using the primers listed in Table II. The PCR products were
then cut by the restriction enzymes for which recognition sites were
designed in the respective primer pairs (see Table II) and subsequently
introduced by ligation into cut standard vectors (pUC18 or pBluescript
II KS), and the inserts were inserted into pET16bP to create reading
frames with N-terminal His-tagged fusions. The resulting plasmids
were transformed and propagated in E. coli DH5. The correctness of
the nucleotide sequences of the inserts was controlled by DNA sequenc-
ing. The resulting His-tagged fusion cassettes were cut out by the
enzyme pairs and further ligated to the streptomycete expression
vectors given in Table I for later transformation and expression in
S. lividans 66 strains. Automated DNA sequencing was carried out on
an A.L.F.-Express machine (Amersham Biosciences, Freiburg, Ger-
many) using the Thermosequenase DNA sequencing kit (Amersham
Biosciences) and standard primers.
Preparation of Cell Extracts and Overexpression of
Proteins in S. lividans
Cells were harvested by centrifugation, resuspended in 0.1 volume of
disruption buffer (25 mM Tris-HCl, 10 mM MgCl2, 20 mM NH4Cl, and 1
mM -mercaptoethanol, pH 7.6), and disrupted by sonication (2–3 min
at 60 watts). Cell-free extracts were obtained after centrifugation at
13,000  g for 1 h at 4 °C. The extracts were dialyzed against 5 liters of
disruption buffer overnight at 4 °C. The proteins were analyzed by
SDS-PAGE as described previously (5, 16). Protein concentrations were
determined according to the method of Bradford (17).
TABLE I
Bacterial strains and plasmids
Strain/plasmid Properties/product Source/Ref.
Bacterial strains
Actinoplanes sp. SE50/
110
Acarbose ATCC 31044
S. lividans 66 1326 Actinorhodin, prodigiosin 11
S. lividans TK23 Actinorhodin, prodigiosin spc-1 11
S. lividans TK64 Actinorhodin, prodigiosin spc-2, pro-2, str-6 11
E. coliBL21(DE3)/pLysS T7 RNA polymerase, cat 21
E. coli DH5 F 80d, lacZM15, endA1, recA1, hsdR17 (rk
mk
), supE44, thi-1,  ,
gyrA96, relA1, D(lacZYA-argF)U169
22
E. coli JM109 F traD36, lacZM15, proAB lac1    recA1, hsdR17 (rk
 mk
),
supE44, thi-1, gyrA96, relA1, (lac)
22
Plasmids
pBluescript II SK bla, lacZ-, f1 ori 24
pET11aP bla, lacZ-, T7 promoter 25
pET16bP bla, lacZ-, T7 promoter, His-tagged fusion peptide 25
pJOE2702 bla, rrnB, rha-p 26
pIJ4123 kan, tsr, tipAp 13
pIJ6021 kan, tsr, tipAp 13
pUC18 bla, lacZ- 23
pUWL201RBSA bla, lacZ-, tsr, ermEp 27
pPWW49 bla, lacZ-, tsr, ermEp, eryBIV 27
pPWW50 bla, lacZ-, tsr, ermEp, eryBIV 27
pAS8/7 acbC in pIJ6021 5
pCWL16 1.42-kb NdeI/SstI fragment from pMJL1 in pET16bP (NdeI/SstI) This work
pCWN16 0.86-kb NdeI/BamHI fragment from pMJN1 in pET16bP (NdeI/BamHI) This work
pCWO16 0.87-kb NdeI/BglII fragment from pMJO1 in pET16bP (NdeI/BamHI) This work
pCWM16 1.08-kb NdeI/KpnI fragment from pMJM1 in pET16bP (NdeI/KpnI) This work
pCWK11 1.0-kb NdeI/BglII acbK fragment in pET11aP (NdeI/BamHI) This work
pCWK16 1.0-kb NdeI/BglII acbK fragment in pET16bP (NdeI/BamHI) This work
pCW201L 1.1-kb NdeI/HindIII acbL fragment in pUWL201RBSA (NdeI/HindIII) This work
pCW201M 1.08-kb NdeI/HindIII acbM fragment in pUWL201RBSA (NdeI/HindIII) This work
pCW201O 0.82-kb NdeI/HindIII acbO fragment in pUWL201RBSA (NdeI/HindIII) This work
pCW2072K 1.0-kb NdeI/BglII acbK fragment in pJOE2702 (NdeI/BamHI) This work
pCW201KM6 1.98-kb NdeI/HindIII acbKM fragment in pUWL201RBSA
(NdeI/HindIII)
This work
pCW4123L 1.42-kb NdeI/EcoRI acbL fragment in pIJ4123 (NdeI/EcoRI) This work
pCW4123M 1.08-kb NdeI/EcoRI acbM fragment in pIJ4123 (NdeI/EcoRI) This work
pMJL1 1.42-kb acbL PCR fragment in pUC18 (SmaI) This work
pMJM1 1.07-kb acbM PCR fragment in pBluescript SK (EcoRV) This work
pMJN1 0.86-kb acbN PCR fragment in pBluescript SK (EcoRV) This work
pMJN2 0.86-kb NdeI/BamHI acbN fragment in pET11aP (NdeI/HindIII) This work
pMJN5 0.86-kb NdeI/BamHI acbN in pPWW50 (NdeI/BamHI) This work
pMJO1 0.87-kb acbO PCR fragment in pBluescript SK (EcoRV) This work
pMJO7 0.87-kb NdeI/BglII acbO fragment in pIJ4123 (NdeI/BamHI) This work
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Enzyme Assays
Generally, the crude extracts as prepared above were tested in as-
says of 20-l final volume in a standard buffer system containing 25 mM
Tris-HCl, 10 mM MgCl2, 20 mM NH4Cl, and 10 mM 2-epi-5-epi-valiolone
(or other substrates that were tested) adjusted to pH 7.6. The coen-
zymes and/or cosubstrates (ATP, NAD, NADH, NADP, NADPH, FAD,
or FADH2) were used in final concentrations of 10 mM in the test
volumes.
AcbK—The acarbose 7-kinase AcbK was tested as described by Drep-
per and Pape (18), but without NH4Cl in the buffer.
AcbM—AcbM tests were routinely performed in a volume of 15 l.
Each assay contained 25 mM Tris-HCl, 10 mM MgCl2, 20 mM NH4Cl, 10
mM ATP, 10 mM 2-epi-5-epi-valiolone (or other substrates that were
tested) adjusted to pH 7.6, and 12 l of cell-free extracts. The assays
were incubated at 30 °C for 2–12 h. The reaction was monitored by TLC.
For radioactive assays, 1 l of [-32P]ATP (2.0 Ci; Amersham Bio-
sciences) was added, and only 11 l of cell-free extracts were used.
Radioactively labeled spots were visualized after TLC by autoradiogra-
phy with x-ray films (Hyperfilm, Amersham Biosciences).
AcbO—For assaying the activity of AcbO, a mixture of cells from
S. lividans/pCW4123M and S. lividans/pMJO7 (1:1) was used. Cell
extracts were prepared as described for the AcbM tests. The test con-
ditions and the detection of the reaction product were also identical as
for the analysis of the AcbM-catalyzed reaction.
Thin-layer Chromatography (TLC)
Samples of the enzyme reactions were chromatographed on silica
thin-layer sheets (Merck, Darmstadt, Germany) using solvent I (isobu-
tyric acid and 1 N NH3 in water, 5:3) or solvent II (butanol/ethanol/
water, 9:7:4). The substrates were detected as brown spots after heating
or as blue spots after development using a cerium- and molybdate-
containing reagent (19).
Purification of the His-tagged AcbM Protein
10-ml cell-free extracts from S. lividans TK64/pCW4123M were ap-
plied to an Ni2-HiTrap chelating column (Amersham Biosciences). The
column was first washed with 10–20 ml of starting buffer (20 mM
Na3PO4, 500 mM NaCl, 20 mM NH4Cl, 10 mM imidazole, and 1 mM
-mercaptoethanol adjusted to pH 7.5) and then washed with a linear
gradient of 10–500 mM imidazole in 10 ml of starting buffer and 10 ml
of elution buffer (20 mM Na3PO4, 500 mM NaCl, 20 mM NH4Cl, 500 mM
imidazole, and 1 mM -mercaptoethanol adjusted to pH 7.5). The frac-
tions were analyzed by SDS-PAGE. The His-tagged AcbM protein was
eluted at 200–300 mM imidazole from the column. The partially
purified protein was dialyzed for 24 h against 5 liters of dialysis buffer
(25 mM Tris-HCl, 10 mM MgCl2, 20 mM NH4Cl, and 1 mM -mercapto-
ethanol adjusted to pH 7.6).
Synthesis of 2-epi-5-epi-Valiolone
Method a—The enzyme-catalyzed synthesis of 2-epi-5-epi-valiolone
was performed in a coupled assay using transketolase (EC 2.2.1.1),
ribose 5-phosphate, and hydroxypyruvate to synthesize the substrate
sedo-heptulose 7-phosphate in situ according to the protocol described
previously (20). The cyclization of sedo-heptulose 7-phosphate was per-
formed with cell-free extracts from S. lividans containing the AcbC
protein according to the protocol of Stratmann et al. (5) under the
following specific conditions, The preparative enzyme reaction was per-
formed overnight at 30 °C in a total volume of 30 ml. The assay con-
tained 2 units of transketolase (Sigma, Munich, Germany), 10 mM
hydroxypyruvate (Sigma), 10 mM ribose 5-phosphate (Sigma), 0.5 mM
thiamin pyrophosphate (Sigma), 1 mM MgCl2, 0.025 mM CoCl2, 2 mM
NaF, pH 7.6, and variable amounts of cell-free extracts from strain S.
lividans 1326/pAS8/7 containing overproduced AcbC protein (1). The
reaction was monitored by TLC. The product of the AcbC reaction had
the same RF value (RF  0.53, solvent II) as the chemically synthesized
2-epi-5-epi-valiolone ((5R,2S,3S,4S)-5-(hydroxymethyl)cyclohexanone-
2,3,4,5-tetrol).
Method b—The chemical synthesis of racemic 2-epi-5-epi-valiolone
was performed according to a new protocol, the details of which will be
published elsewhere.1
Purification of 2-epi-5-epi-Valiolone
30 ml of the AcbC reaction solution were heated at 90 °C for 5 min,
centrifuged (5000 rpm, 20 min), and then applied to an ultrafiltration
cell with a YM-10 ultrafiltration membrane (10,000-Da cutoff; Amicon,
Witten, Germany). The flow-through was collected. After freeze-drying,
250 mg of yellow powder were acquired. The product was dissolved in
3 ml of Milli-Q water and then subjected to anion-exchange chromatog-
raphy with Dowex 1-X8 (Cl form, mesh 100–200; Serva, Heidelberg,
Germany) on an SR25/50 column (Amersham Biosciences). The column
was washed with water, and the fractions containing 2-epi-5-epi-vali-
olone were pooled. After lyophilization, 20 mg of 2-epi-5-epi-valiolone
were obtained as a light-yellow powder.
Purification of 2-epi-5-epi-Valiolone 7-Phosphate
The partially purified AcbM protein was used in phosphorylation
assays with 20 mg of purified 2-epi-5-epi-valiolone. The reaction mix-
ture was applied to an Amicon ultrafiltration cell with a YM-10 ultra-
filtration membrane (10,000-Da cutoff). The 10-ml flow-through was
collected, concentrated to 3 ml by freeze-drying, and then subjected to
anion-exchange chromatography with Dowex 1-X8 (Cl form, mesh
100–200) on a SR25/50 column. The column was washed with plenty of
water, and the 2-epi-5-epi-valiolone phosphate was eluted with a linear
gradient of 0–600 mM NaCl at a flow rate of 2 ml/min. The elutions
were collected as 2-ml fractions and analyzed by TLC. Fractions con-
taining the desired product (total volume of 48 ml) were pooled and
concentrated 10-fold by freeze-drying. Desalting the product was car-
ried out at 4 °C on Sephadex G-10 (5.0  81-cm SR25/100 column,
Amersham Biosciences). The product was eluted with water at a flow
rate of 1.5 ml/min. The fractions containing 2-epi-5-epi-valiolone phos-
phate were pooled. After lyophilization, 12 mg of 2-epi-5-epi-valiolone
phosphate were obtained as a white powder.
NMR
All NMR spectra were recorded on a Bruker ARX 400 spectrometer
(400 MHz). In addition to 1H, 13C, and 31P experiments, also COSY
(1H-1H, 1H-13C, and 1H-31P) and distortionless enhancement of polar-
ization transfer (DEPT) spectra for the unequivocal correlation of the
hydrogen, carbon, and phosphor atoms were recorded.
The chemical shifts are given in ppm, related to the solvents as
internal standard. The multiplicity is given by the following symbols: s
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), t
(pseudotriplet for unresolved dd), and br (broad). The coupling constant
J is given in Hz.
The NMR spectra for 2-epi-5-epi-valiolone are as follows: 1H NMR
(d4-MeOH, 400 MHz):  2.33 (dd, 1H, J 13.7, 1.7 Hz, H-6ax), 2.84 (d,
1 O. Block and H.-J. Altenbach, unpublished data.
TABLE II
Primers for amplification of the acb genes investigated
Primer Nucleotide sequencea Target
AcbK1 5-CAAGGAGACATATGTCGGAGCAC-3 acbK start
AcbK2 5-GTGGTGAGATCTTCGCCCAGT-3 acbK stop
2775M1 5-GCCGGCCATATGAAGCGGC-3 acbM start
pMJM1E 5-CGGTGCCGGTACCACGATCGCGC-3 acbM stop
2775L1 5-TTGGTCGGCATATGAGCCGG-3 acbL start
pMJL.1E 5-GTACGGAATTCGTCCACCGCCAC-3 acbL stop
2775N1 5-AGAGGATCACATATGAGCGGGACTC-3 acbN start
pMJN.1E 5-GAGCTGGATCCCGTC-3 acbN stop
2775O1 5-GGTGCGCATATGACCTGCCG-3 acbO start
pMJO.1E 5-TACCGTCTCGACAGATCTCAGTCAGCTTCCT-3 acbO stop
a Introduced recognition sites for restriction endonucleases are underlined.
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1H, J 13.7 Hz, H-6eq), 3.43 (d, 1H, J 11.3 Hz, H-7a), 3.64 (d, 1H, J
11.3 Hz, H-7b), 4.03 (m, 1H, H-4), 4.27 (t, 1H, J 4 Hz, H-3), and 4.59
(d, J 4.0 Hz, H-2); 13C NMR (d4-MeOH, 101 MHz):  46.0 (C-6), 67.7
(C-7), 70.9, 76.1, 79.7 (C-2, C-3, C-4), 81.5 (C-5), and 209.8 (C-1).
The NMR spectra for 2-epi-5-epi-valiolone 7-phosphate are as fol-
lows: 1H NMR (D2O, 400 MHz):   2.38 (d, 1H, J  13.8 Hz, H-6ax),
2.89 (d, 1H, J  14.2 Hz, H-6eq), 3.58 (dd, 1H, J  6.6, 11.7 Hz, H-7a),
3.99 (dd, 1H, J  9.4, 11.5 Hz, H-7b), 4.18 (m, 1H, H-4), 4.38 (t, 1H,
J  3.8 Hz, H-3), and 4.71 (d, under HDO, J  4.0 Hz, H-2); 13C NMR
(D2O, 101 MHz):   46.38 (C-6), 70.17 (d, J  5.1 Hz, C-7), 71.19 (C-4),
76.74 (C-2), 79.62 (C-3), 82.86 (C-5), and 101.23 (C-1); 31P{1H} NMR
(D2O, 162 MHz):   5.55 (PC-7). The optical rotation of 2-epi-5-epi-
valiolone 7-phosphate was []D
20  4.9° (C, 0.35, IN H2O).
Ion Chromatography
The chromatographic part consisted of a Dionex DX-500 ion chroma-
tography system equipped with a gradient pump (GP40), an eluent
generator (EG40) with an EGC-KOH cartridge, a 25-l injection loop,
and an electrochemical conductivity detector (ED40). Chromatographic
separation was performed on a Dionex Ion Pac AS11 column (250  2
mm) provided with a guard column (AG11). An anion trap column
(ATC-1) was placed in-line with the GP40 pump and the injection valve
to remove anionic contaminants from the eluent. Microfiltered (0.2 m)
water with a specific resistance of at least 18 milliohms was used. The
gradient was run as shown in Table II. The Dionex ASRS-II self-
regenerating chemical suppressor was housed in an LC30 chromatog-
raphy oven at 35 °C and operated in the external water mode at 100
mA. The samples were analyzed in triplicate at a flow rate of 0.25
ml/min. The following KOH gradient profile was used: 0–2 min at 100
mM, 2–9 min at 1 mM (point of injection), 9–11 min at 1 mM, 11–15 min
increasing from 1 to 19 mM, 15–18 min increasing from 19 to 20 mM,
18–25 min increasing from 20 to 100 mM, and 25–26 min at 100 mM.
Mass Spectrometry
The experiments were performed on a PE-Sciex API 2000 triple-quad
instrument (Applied Biosystems, Langen, Germany) equipped with a
Turbolon ion spray and heated nebulizer. To avoid current leakage, the
connection tube between the ion chromatograph and the mass spec-
trometer had to be grounded directly behind the ED40 detector. All
measurements were made in the negative scan mode. Hyphenation was
realized with the original flow rate of 0.25 ml/min at a heater temper-
ature of 380 °C and a Turbolon ion spray voltage of –4000 V. Optimal
gas (N2) pressures were found as follows: nebulizer gas at 30 p.s.i.,
heater gas at 90 p.s.i., and curtain gas at 45 p.s.i. Especially for mass-
reaction-mass (MRM) measurements, the collision-added dissociation
gas rate was set at 3 p.s.i.
RESULTS
Identification of AcbK as the Acarbose 7-Kinase—The gene
cluster for the synthesis and metabolism of acarbose and re-
lated components of the amylostatin complex of the producer
Actinoplanes sp. SE50/110 has been cloned on a single cosmid
and fully sequenced recently.2 Its function was proven by het-
erologous expression from the cosmid in S. lividans TK23,
which formed acarbose-related substances and characteristic
enzyme activities involved in acarbose metabolism such as the
extracellular acarviosyltransferase AcbD (28), and the cyto-
plasmic acarbose 7-kinase (18, 19). The gene for the acarbose
7-kinase, acbK, was identified in a putative operon, acbKLM-
NOC (GenBankTM/EBI accession number Y18523) (Fig. 2), by
the identity of the first 20 amino acids of the N-terminal pep-
tide sequence obtained from the purified enzyme by others (18)
to that of the deduced AcbK protein sequence. Also, AcbK
exhibited significant similarity to members of the ribokinase
family of phosphotransferases (Fig. 3A). Therefore, we con-
structed various plasmids for the expression of AcbK in recom-
binant derivatives of both E. coli (BL21(DE3)/pLysS/pCW11K,
BL21(DE3)/pLysS/pCW16K, and JM109/pCW2072K) and S.
lividans (TK23/pCW201KM6) (cf. Table I). In all host strains,
heterologous (over)expression of soluble AcbK protein, which
was active with or without an N-terminal His tag extension,
could be achieved (Fig. 4A). The host strains lacked any back-
ground activity for phosphorylation of acarbose. The acarbose
7-kinase AcbK did not phosphorylate 2-epi-5-epi-valiolone or
any of the other possible cyclitol precursors tested in this study
in both assay systems used (Table III; cf. Fig. 1C).
Identification of AcbM as a 2-epi-5-epi-Valiolone Kinase—
The genes acbLMNO, bracketed by the functionally character-
ized acbK and acbC genes, were among those putative acarbose
biosynthetic genes with some likelihood of being involved in the
cyclitol pathway because of their location and the similarities of
the encoded AcbL, AcbM, and AcbN proteins to known enzymes
(cf. Figs. 2 and 3). The proteins AcbN and AcbL exhibited
significant similarities to known oxidoreductases, belonging to
two different subfamilies of the dehydrogenases with an N-
terminal dinucleotide-binding fold, the zinc-dependent and
short-chain alcohol dehydrogenases, respectively (data not
shown). AcbM exhibited a distant similarity to GlcK from Ba-
cillus subtilis (GenBankTM/EBI accession number P54495) and
other glucokinases, being a member of the hexose 6-kinase
family of phosphotransferases (Fig. 3B). No data base entries
significantly similar to AcbO were found with all methods of
similarity search used (BLAST and fasta 3).
It is known that 2-epi-5-epi-valiolone is the first intermediate
in the cyclitol pathway of acarbose, leading to valienol or va-
lienamine (5). It was speculated that the first reaction after the
formation of 2-epi-5-epi-valiolone might be catalyzed by either
a dehydratase or a dehydrogenase, followed by a step catalyzed
by an epimerase (5, 9). To determine whether the next conver-
sion step was catalyzed by AcbL, AcbM, AcbN, or AcbO, the
corresponding genes (acbLMNO) were cloned separately in var-
ious E. coli expression vectors (pET11a, pET11aP, or pET16bP)
(Table I). However, when using these plasmids, none of the
proteins could be produced as soluble proteins, although a
number of variations in the culture conditions had been tested.
Therefore, the genes were cloned in suitable streptomycete
expression vectors (pUWL201, pPWW50, and pIJ4123) (cf. Ta-
ble I) and overexpressed in S. lividans strain TK23, TK64, or
1326. All proteins were well expressed especially when the
recombinant pIJ4123 derivatives for the production of N-ter-
2 H. Thomas, U. F. Wehmeier, A. Stratmann, M. Jarling, and W.
Piepersberg, unpublished data.
FIG. 2. Genetic organization of genes acbKLMNOC. The genes
are symbolized by arrows. The putative proteins encoded by the genes
and their postulated functions are listed below. The genes are part of
the putative transcription unit acbKLMNOC in the acb gene cluster
(GenBankTM/EBI accession number Y18523). The recognition sites for
the restriction endonucleases BglII and SstI in this DNA segment are
shown.
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minal His-tagged fusion proteins were used (Fig. 4, B–D).
Extracts from S. lividans TK23 with pMJN5 (acbN) and from
S. lividans TK64 harboring pCW4123M (acbM), pCW4123L
(acbL), or pMJO7 (acbO) were prepared and used in a number
of various enzyme assays (dehydration, reduction, epimeriza-
tion, or phosphorylation assays), including chemically synthe-
sized cyclitols (cf. Fig. 1C) and combinations of the coenzymes
ATP, NAD(P), NAD(P)H, FAD, and FADH2. In these tests,
extracts containing a single overproduced Acb protein and also
combinations of the various extracts were analyzed. The en-
zyme tests were monitored by TLC and also photometrically. In
none of the assays was a dehydrogenase-, an epimerase-, or a
dehydratase-like activity detected (data not shown). However,
when chemically synthesized 2-epi-5-epi-valiolone was incu-
bated with cell extracts including AcbM and ATP as a cosub-
strate, a new product was observed upon TLC (Fig. 5). This
product was missing in all assays lacking ATP. Therefore, we
assumed that the new product was 2-epi-5-epi-valiolone phos-
phate. In subsequent assays using [-32P]ATP, we determined
that the new product was indeed radioactively labeled. This
clearly showed that 2-epi-5-epi-valiolone was phosphorylated.
We also tested the phosphorylation of other cyclitols (2-epi-5-
epi-valiolol, 5-epi-valiolol, 1-epi-2-epi-5-epi-valiolol, 1-epi-5-epi-
valiolol, 1-epi-valienol, and valienol) (Fig. 1C and Table III) in
assays with AcbM extracts. In the presence of [-32P]ATP, only
in assays with 2-epi-5-epi-valiolol and 1-epi-2-epi-5-epi-valiolol
were weak radioactively labeled spots detected on the autora-
diogram of the TLC separation. In nonradioactive assays, these
spots were not visible, indicating very low and less specific
phosphorylation of these compounds (Table III). As the chem-
ically synthesized 2-epi-5-epi-valiolone consisted of a racemic
mixture, only 50% of the substrate used in the assays was
converted (cf. Fig. 5). To overcome this problem, we synthesized
enantiomerically pure 2-epi-5-epi-valiolone enzymatically. In a
coupled assay (see “Materials and Methods”), 2-epi-5-epi-vali-
olone was synthesized, and the purified product was incubated
with AcbM-containing extracts. In these assays, the conversion
of 2-epi-5-epi-valiolone to the new phosphorylated spot upon
TLC was nearly 100% (cf. Fig. 5). This result clearly demon-
strated that the enzymatically produced 2-epi-5-epi-valiolone
was the substrate for this phosphorylation step.
Purification and Structural Characterization of Phosphoryl-
ated 2-epi-5-epi-Valiolone—To prepare 2-epi-5-epi-valiolone
phosphate from a purified system and to identify the position of
the phosphate, the substrate 2-epi-5-epi-valiolone was enzy-
matically synthesized and purified on a preparative scale, and
the His-tagged AcbM enzyme was purified via its affinity for
Ni2-agarose (see “Materials and Methods”) (Fig. 6). These
were used in scaled-up phosphorylation assays. From these
assays, the phosphorylated product was isolated and purified
as described under “Materials and Methods.” The product was
first characterized by ion chromatography-mass spectrometry.
The ion chromatography-mass spectrometry data showed that
a substance with a molecular mass of 272 Da was generated.
This mass corresponds exactly to the calculated mass for 2-epi-
5-epi-valiolone phosphate. Then 1H, 13C, and 31P NMR data for
the purified substance were determined (see “Materials and
Methods”) (Fig. 7). In the 1H NMR spectrum, the coupling
pattern of the former hydroxymethyl group changed signifi-
cantly, indicating that it had been modified. A signal in the 31P
NMR at 5.55 ppm is indicative of a phosphate group, and a
1H-31P COSY experiment proved that the phosphate group sits
at the primary position. The methylene group occurred in the
1H NMR as an ABX spin system at 3.58 and 3.99 ppm with
coupling constants 3JH-7a,P  6.6 Hz and
3JH-7b,P  9.4 Hz,
respectively. Interestingly, while dissolving in D2O, the AB
FIG. 3. Alignment of the AcbK and AcbM protein sequences
with those of other kinases. A, the AcbK sequence is significantly
related to members of the ribokinase family (COG0524; www.ncbi.nlm.
nih.gov/COG) (30). A consensus (consens) sequence is given for residues
identical in at least four of the aligned five sequences. B, the AcbM
sequence is distantly related to members of the glucokinase family
(COG1940). A consensus sequence is given for residues identical in all
three sequences. The sequences aligned are from the following sources:
AcbKAsp, AcbK protein from Actinoplanes sp. SE50/110 (GenBankTM/
EBI accession code Y18523); MTH404, putative ribokinase from Meth-
anobacterium thermoautotrophicum (accession code AAB84910);
PAB0280, putative ribokinase from Pyrococcus abyssi (accession code
E75157); MTH1544, putative ribokinase from M. thermoautotrophicum
(accession code AAB86018); CC3733, putative ribokinase from Cau-
lobacter crescentus (accession code AAK25695); GlkASli, glucokinase
from S. lividans TK24 (accession code AAF42869); GlcKBsu, putative
glucokinase from B. subtilis 168 (accession code P54495); AcbMAsp,
AcbM protein from Actinoplanes sp. SE50/110 (accession code Y18523).
Biosynthesis of the C7-cyclitol Moiety22858
 at R
sch Cntr Julich Res library on August 6, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
pattern of the ring methylene group was replaced by two
pseudosinglets at 2.40 and 2.78 ppm within 30 min. This phe-
nomenon can be explained by a fast exchange of the methylene
protons by deuterium from the solvent and has also been ob-
served for the 2-epi-5-epi-valiolone system itself (6). In the 13C
spectrum, C-7 appears as a doublet at 70.2 ppm with coupling
constant 2JC-7,P  5.1 Hz. Instead of the expected carbonyl
group, C-1 shows a resonance for a quaterneric carbon at
101.23 ppm, indicating a hydratization of the ketone function.
From the described results, the purified product of the AcbM
reaction can be unequivocally identified as 2-epi-5-epi-valiolone
7-phosphate, the second intermediate in the cyclitol branch of
the acarbose pathway.
2-epi-5-epi-Valiolone 7-Phosphate Is the Substrate of
AcbO—To obtain further insight into the biosynthetic pathway
for valienol, cell extracts containing AcbM were combined with
extracts containing AcbO, AcbL, or AcbN. In all tests, 2-epi-5-
epi-valiolone and ATP were used as substrates without or in
combination with various dinucleotides as redox or epimerase
coenzymes (NAD, NADH, NADP, and NADPH). Only when
extracts with AcbM/ATP in combination with AcbO were used
was a new spot observed on the TLC plates (Fig. 5). Without
AcbM and in the presence of ATP alone, no conversion of
2-epi-5-epi-valiolone by AcbO was monitored. These data give
an important hint for AcbO being the next enzyme in cyclitol
conversion. In these assays, no dinucleotide coenzyme was
required, although extensively dialyzed cell extracts were used.
This finding indicated that the reaction catalyzed by AcbO was
coenzyme-independent or that if a cofactor was involved, it
must have been tightly bound to the enzyme. Therefore, it was
further investigated whether AcbO could be either (i) the epi-
merase that catalyzes the epimerization at C-2 to give 5-epi-
valiolone phosphate or (ii) a dehydratase that catalyzes the
formation of 2-epi-valienone 7-phosphate.
Characterization of the AcbO Product as a Probable Epimer
of 2-epi-5-epi-Valiolone 7-Phosphate—To identify the conver-
sion product from 2-epi-5-epi-valiolone 7-phosphate that was
obtained in the reaction catalyzed by AcbO, the ion chromatog-
raphy-mass spectrometry data of the reaction product were
analyzed. In assays containing 2-epi-5-epi-valiolone/ATP and
the overproduced enzyme AcbM alone or AcbM and AcbO to-
gether, three new mass peaks of phosphorylated compounds
were detected: m/z 253 (13.27 min), 271 (12.77 min; 2:1 ratio),
and 287 (12.97 min). These peaks were missing in assays
without AcbM. The dominant mass peak (m/z 271) corre-
sponded exactly to the expected mass for 2-epi-5-epi-valiolone
7-phosphate. As the same mass peak (m/z 271) was detected in
assays with AcbO, we concluded that AcbO most likely cata-
lyzed the epimerization at C-2, yielding 5-epi-valiolone
7-phosphate.
DISCUSSION
Earlier work has demonstrated that 2-epi-5-epi-valiolone is
the precursor of the C7-cyclitol unit of the acarviosyl moiety of
acarbose (5, 8). The expectation was that a series of enzyme-
catalyzed steps involving dehydration, reduction, and epimer-
ization converted this precursor to valienol (or valienamine)
before its incorporation into the pseudodisaccharide acarvi-
osine. Although a number of feeding experiments with possible
intermediates were described, all other steps and intermedi-
ates of this biosynthetic route remained unclear so far (8).
In this study, we have shown that, unexpectedly, the second
step after initial formation of the cyclitol precursor by the
FIG. 4. SDS-PAGE analysis of the production of proteins AcbK,
AcbM, AcbL, AcbN, and AcbO in S. lividans. Electrophoresis was
run on a 10% polyacrylamide gel. A, production of AcbK in S. lividans
TK23. Soluble proteins were separated from S. lividans TK23 harbor-
ing pUWL201 (control; lane 1) or pCW201KM6 (AcbK; lane 2). B,
production of AcbM and AcbL in S. lividans TK64. Soluble proteins
from cells harboring plasmid pIJ4123 (control; lane 1), pCW4123L
(N-terminal His-tagged AcbL; lane 2), or pCW4123M (N-terminal His-
tagged AcbM; lane 3) were subjected to PAGE. C, production of AcbN in
S. lividans TK23 harboring pMJN5 (N-terminal His-tagged AcbN; lane
1). D, production of AcbO in S. lividans TK64 harboring plasmid pMJO7
(N-terminal His-tagged AcbO; lane 1). The molecular masses of the
marker proteins (lanes M) are indicated in kDa. The respective overex-
pressed Acb proteins are depicted by arrows.
FIG. 5. TLC analyses of AcbM and AcbO assays. Extracts from
S. lividans TK64 with pIJ4123 (control), pCW4123M (AcbM), or pMJO7
(AcbO) were used for these assays. Samples were prepared as described
under “Materials and Methods.” Samples were applied to TLC sheets
and separated using solvent II (see “Materials and Methods”); spots of
cyclitol components were visualized using a cerium/molybdate-contain-
ing reagent (19). The respective spots are marked by arrows. For assays
shown in lanes 2-6, enzymatically synthesized 2-epi-5-epi-valiolone was
used; for assays shown in lanes 7-11, chemically synthesized 2-epi-5-
epi-valiolone was used. Lane 1, 4 l of ADP (10 mM); lanes 2–11, 4 l of
the reaction mixtures of complete assays with cell extracts from strains
containing plasmids pIJ4123, pMJO7, pCW4123M, pCW4123M (with-
out ATP), pCW4123M/pMJO7, pCW4123M/pMJO7, pCW4123M,
pCW4123M (without ATP), pMJO7, and pIJ4123, respectively; lane 12,
4 l of ATP (10 mM).
TABLE III
Phosphorylation assays with AcbK and AcbM
All substrates were used in phosphorylation assays with unlabeled
ATP and [-32P]ATP as described under “Materials and Methods” ,
phosphorylation; 	, weak phosphorylation, detectable only with
[-32P]ATP; , no phosphorylation.
Substrate
Phosphorylation by
AcbK AcbM
2-epi-5-epi-Valiolone  
2-epi-5-epi-Valiolol  	
1-epi-2-epi-5-epi-Valiolol  	
1-epi-5-epi-Valiolol  
5-epi-Valiolol  
1-epi-Valienol  
Valienol  
Acarbose  
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cyclase AcbC represents a modification by phosphorylation.
The reaction involves the conversion of 2-epi-5-epi-valiolone to
2-epi-5-epi-valiolone 7-phosphate, which is catalyzed by a novel
kinase, AcbM. The AcbM polypeptide chain shows distant sim-
ilarity to some members of the hexokinase family of sugar
phosphotransferases, which form a cluster of orthologs in com-
plete genome sequences (COG1940; www.ncbi.nlm.nih.gov/
COG) (30). This similarity is intriguing because both enzymes
D-glucose 6-kinase (GlcK) and 2-epi-5-epi-valiolone 7-kinase
(AcbM) phosphorylate the primary hydroxyl group on a cyclic
polyol with a six-member ring system. This might indicate that
not only valienol, but also its precursor 2-epi-5-epi-valiolone,
has a distinct structural resemblance to hexoses. The C7-cycli-
tol unit of acarbose and its precursors behave functionally as
sugar-related metabolites, which are metabolized inside cells
mainly as their phosphorylated or nuleotidylated forms. The
same position of the cyclitol moiety of free acarbose molecules
is also phosphorylated inside cells by the acarbose 7-kinase,
encoded by the acbK gene in the same putative transcription
unit together with acbM and some other genes (cf. Fig. 2) (Refs.
19 and 29 and this work). During tests for the substrate spec-
ificity of AcbK, others had measured a weak activity also with
two C7-cyclitols not directly related to valienol metabolism and
with a derivative of acarbose lacking the valienol moiety (19).
These assays had been carried out with an indirect measure-
ment of ATP consumption, and no direct determination of the
phosphorylated products was achieved. However, in our hands,
AcbK acted only on the oligomeric end product acarbose and
not on any of the monomeric C7-cyclitols that are likely precur-
sors of valienol or on valienol itself. In contrast, AcbM seems to
phosphorylate a monomeric cyclitol and to be specific only for
the first cyclic intermediate of valienol biosynthesis, 2-epi-5-
epi-valiolone, but not for any other monomeric C7-cyclitols.
Therefore, we conclude that AcbM is a biosynthetic enzyme,
whereas AcbK has another, possibly protective and/or trans-
port-prone function(s) (see below).
Further conversion of the cyclitol precursor 2-epi-5-epi-vali-
olone 7-phosphate is catalyzed by the isomerase AcbO, which is
possibly a 2-epimerase. This conversion step was unexpected
because it seemed more likely that either dehydration at posi-
tions 5 and 6 or reduction of the keto group at position 1 of the
cyclitol came first. The fact that 2-epi-5-epi-valiolone is first
phosphorylated and only thereafter further modified by other
biosynthetic enzymes such as AcbO is in good accordance with
all feeding experiments with whole cells that have been per-
formed so far (8). In these studies, 2-epi-5-epi-valiolone was the
only extracellularly provided C7-cyclitol that was incorporated
into acarbose. In contrast to these results, in addition to the
identical starter metabolite 2-epi-5-epi-valiolone, some addi-
tional intermediates (5-epi-valiolone and valienone) were incor-
porated into the trehalase inhibitor validamycin A, although it
shares the same cyclitol moiety, valienol (or valienamine) (cf.
Fig. 1) (6). Therefore, the biosynthesis of the two C7-cyclitol
units (valienamine and validone) seemed to occur without ini-
tial phosphorylation by direct epimerization and dehydration
or reduction (7). Also, the incorporation of the nitrogen into
validamycin must occur on another route because, in acarbose,
it is introduced via formation of a dideoxyaminohexose (see
below). So, if phosphorylated cyclitol intermediates are used,
e.g. before condensation, they occur in a later phase; and as
compared with acarbose synthesis in Actinoplanes sp. SE50/
110, a completely different pathway seems to be used in the
validamycin producer S. hygroscopicus ssp. limoneus.
The 7-phosphorylation of the C7-cyclitol moiety during the de
novo synthesis of acarbose could be necessary to prevent an
inhibitory effect of the C7-cyclitol- and acarviosyl-containing
intracellular metabolites on cytoplasmic enzymes sensitive to
those inhibitors, such as -glucosidases and glucomaltases of
the producer. For instance, after 7-phosporylation of acarbose
by AcbK, the cytoplasmic and acarbose-sensitive maltase ac-
tivity of Actinoplanes sp. SE50/110 is no longer strongly inhib-
ited by the modified inhibitor (19). Therefore, this phosphoryl-
ation can be regarded as a resistance-like self-protection
FIG. 6. Schematic diagram of affinity chromatography and
SDS-PAGE analysis of the purification of His-tagged AcbM. Pu-
rification was performed as described under “Materials and Methods.”
An elution chromatogram of His-tagged AcbM from an Ni2-HiTrap
chelating column is shown. The linear gradient of 10–500 mM imidazole
is indicated by a broken line. The fractions containing His-tagged AcbM
are indicated by dotted lines. 1-ml fractions were collected as indicated.
The inset shows the results from SDS-PAGE analysis of the elution
fractions. Electrophoresis was run on 10% protein gel. Lane A, cell-free
extracts from S. lividans TK64/pIJ4123; lane B, cell-free extracts from
S. lividans TK64/pCW4123M; lane M, protein molecular mass marker
(sizes indicated in kDa); lane FL, flow-through; lanes 2, 9, and 10–13, 14
l of the elution fractions corresponding to those shown in the chromat-
ogram. The His-tagged AcbM protein is depicted by arrows.
FIG. 7. 1H-31P COSY NMR spectrum of 2-epi-5-epi-valiolone
7-phosphate.
Biosynthesis of the C7-cyclitol Moiety22860
 at R
sch Cntr Julich Res library on August 6, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
mechanism similar to those in other aminoglycoside producers
(3, 31). It was shown earlier that the 6-phosphorylations of both
streptomycin precursors and streptomycin itself in Streptomy-
ces griseus strains, which also are catalyzed by a biosynthetic
6-kinase (probably StrN) acting on a monomeric cyclitol inter-
mediate (N-amidinostreptamine) and a resistance-conferring
6-kinase (AphD), always keep the bioactive metabolites in an
inactivated state intracellularly (reviewed in Refs. 3 and 32). In
addition, (dihydro)streptomycin 6-phosphate seems to be the
export form of this antibiotic. It becomes dephosphorylated to
the bioactive form only by a specific phosphatase (StrK) outside
the cell (33). This coupling of resistance and active export
mechanisms seems to be a widespread strategy used in produc-
ers of self-toxic metabolites. Similar modes are used also in the
producers of macrolides (by glucosylation) (34) and puromycin
and phosphinothricin (by acetylation) (35, 36). Therefore, we
speculate that the 7-phosphorylation of acarbose-related me-
tabolites (the intracellular end product of the underlying path-
way has not yet been identified) has, in addition, a role in their
export to the environment.
Acarbose can be regarded both physiologically and structur-
ally as a member of the aminoglycoside group of bacterial
products (3–5). For instance, the three subunits of streptomy-
cin, before condensation, are either phosphorylated (strepti-
dine 6-phosphate) or nucleotidylated (dTDP-L-dihydrostreptose
or dTDP-L-rhamnose and nucleoside diphosphate-N-methyl-L-
glucosamine). Condensation occurs via typical glycosyltrans-
ferase-catalyzed reactions. In the new pathway for acarbose,
which we present here, the subunits are phosphorylated and/or
activated by nucleotidylation and condensed by glycosyl trans-
fer, too. The postulated cyclitol transferase AcbS (related to
bacterial glycosyltransferases; COG0297) would catalyze the
last step.
From the data presented herein and from the analysis of the
whole acb cluster, we propose a new pathway for the biosyn-
thesis of the acarviosyl unit of acarbose (Fig. 8). The main
characteristics of our suggestion for this biosynthesis are (i) the
phosphorylation of 2-epi-5-epi-valiolone at C-7 prior to its mod-
ification; (ii) the further modification of the cyclitol 7-phosphate
intermediate by 2-epimerization, 5,6-dehydration, and 1-reduc-
tion, resulting in 1-epi-valienol 7-phosphate; (iii) a second phos-
phorylation and a subsequent nucleotidylation step at C-1 in
1-epi-valienol 7-phosphate; and (iv) the incorporation of the
amino nitrogen into the sugar moiety and not into the cyclitol
unit. Evidence for the phosphorylation of 2-epi-5-epi-valiolone
and its further conversion products has been presented in this
work. In additional experiments, we have found evidence that
1-epi-valienol is phosphorylated by a crude extract from Acti-
noplanes sp. SE50/110 (data not shown); experiments with
1-epi-valienol 7-phosphate as the more likely substrate (be-
cause extracellularly applied 1-epi-valienol is not incorporated)
(8) in similar assays are in progress. Phosphorylation at C-1
would be a prerequisite for a subsequent nucleotidylation step.
In the acb cluster, we have identified the gene acbR, which
encodes a GlgC (ADP-glucose synthase; COG0448)-like protein,
which could catalyze the nucleotidylation of the likely precur-
FIG. 8. Proposed pathway for the
biosynthesis of the pseudodisaccha-
ridic acarviosyl moiety of acarbose.
The scheme shows the postulated biosyn-
thesis for the acarviose moiety starting
from the first known intermediate, 2-epi-
5-epi-valiolone (5). Postulated steps are
symbolized by enzyme names with ques-
tion marks; for unknown enzymatic steps,
all putative enzymes are given. If only one
gene product with a question mark is
given for one step (AcbR and AcbS), then
this enzyme exhibits similarities to en-
zymes with similar functions and there-
fore is the most likely candidate for this
reaction (see “Discussion”). The secondary
amino-N is likely to be introduced via the
6-deoxyhexose unit because synthesis of
dTDP-4-amino-4,6-dideoxy-4-amino-D-
hexose by catalysis of amino transfer from
L-glutamic acid to dTDP-4-keto-6-deoxy-
D-glucose by AcbV was shown to occur by
Diaz-Guardamino and Piepersberg (see
Footnote 3).
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sor 1-epi-valienol 1,7-diphosphate. We also have experimental
evidence that the gene acbV encodes a GabT-like aminotrans-
ferase, which uses dTDP-4-keto-6-deoxyglucose and L-gluta-
mate as substrates for the synthesis of dTDP-4-amino-4,6-
dideoxy-D-glucose.3 From all these data, it seems most likely
that the acarviose is the condensation product of nucleoside
diphosphate-1-epi-valienol 7-phosphate and dTDP-4-amino-
4,6-dideoxy-D-glucose. The putative glycosyltransferase AcbS is
postulated to fulfill this function. It is still unclear whether
acarviose (or activated acarviose or acarviose 7-phosphate) or
acarbose is the final product that is synthesized inside the cell.
So far, we do not know if the glucose or maltose moieties of
acarbose are introduced inside the cell or after the export of the
activated acarviose. If acarviosylglucose 7-phosphate is the
exported product, the acarviosyltransferase AcbD described by
Hemker et al. (28) could be a candidate that adds, via transg-
lycosylation, the maltose or maltotriose residues to the acarvio-
syl unit outside the cell to form acarbose and the higher order
oligomeric components found in the fermentation broth of Ac-
tinoplanes sp. SE50/110.
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